Clinical Trials

A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)


Research Study Number:
PRO2017-0799

Short Title:
DUPLEX

Division:
Nephrology

Study Status:
Pending